Särkilä Hanna, Taipale Heidi, Tanskanen Antti, Kurko Terhi, Taiminen Tero, Tiihonen Jari, Sund Reijo, Saastamoinen Leena, Hietala Jarmo, Niemelä Solja
Department of Psychiatry, Clinical Institute, University of Turku, Turku, Finland.
Department of Psychiatry, Turku University Hospital, Turku, Finland.
BJPsych Open. 2024 Sep 23;10(5):e158. doi: 10.1192/bjo.2024.780.
A nationwide register-based cohort study from Finland including 48 124 incident benzodiazepines and related drug (BZDR) users aged 18-65 years who initiated use in 2006 and were not dispensed BZDRs during 2004-2005. The follow-up was 5 years or until death, whichever occurred first.
To investigate sociodemographic and clinical factors associated with high-dose use of BZDRs (i.e. Z-drugs) among new BZDR users.
The temporal BZDR dose was calculated as a point estimate every 6 months after initiation as defined daily doses (DDDs) per day, based on the PRE2DUP method (an approach based on mathematical modelling of personal drug purchasing behaviours). Sociodemographic and clinical factors associated with dose categories were studied using multinomial logistic regression.
During the 5-year follow-up, very high-dose BZDR use was observed in 7.4% ( = 3557) and medium high-dose use in 25.5% ( = 12 266) of the users (corresponding to ≥30 mg and 10-29 mg in diazepam equivalents, respectively). Very high-dose use was more common among men compared with women (10.9% versus 4.6%). Very high-dose use patterns were especially observed in younger age groups (18- to 25-year-olds). Compared with oxazepam, initiating BZDR use with clonazepam (adjusted odds ratio 3.86, 95% CI 3.24-4.60), diazepam (2.05, 1.78-2.36) or alprazolam (1.76, 1.52-2.03) was associated with increased odds for very high-dose use. Both medium high-dose and very high-dose BZDR use were associated with a lower level of education. In all, 58% of very high-dose use occurred in BZDR users who received their first prescription from general practitioners.
Clinicians should be aware of the dose escalation risk especially when prescribing diazepam, alprazolam or clonazepam for psychiatric indications. If BZDRs are needed, our findings suggest favouring oxazepam.
一项来自芬兰的全国性基于登记的队列研究,纳入了48124名年龄在18至65岁之间的苯二氮䓬类及相关药物(BZDR)新使用者,他们于2006年开始使用该类药物,且在2004 - 2005年期间未使用过BZDR。随访期为5年或直至死亡,以先发生者为准。
调查新BZDR使用者中与高剂量使用BZDR(即Z类药物)相关的社会人口学和临床因素。
根据PRE2DUP方法(一种基于个人药物购买行为数学建模的方法),将起始使用后每6个月的BZDR剂量计算为每日限定日剂量(DDD)的点估计值。使用多项逻辑回归研究与剂量类别相关的社会人口学和临床因素。
在5年随访期间,7.4%(n = 3557)的使用者出现极高剂量BZDR使用,25.5%(n = 12266)的使用者出现中高剂量使用(分别相当于地西泮等效剂量≥30mg和10 - 29mg)。与女性相比,极高剂量使用在男性中更为常见(10.9%对4.6%)。极高剂量使用模式尤其在较年轻年龄组(18至25岁)中观察到。与奥沙西泮相比,起始使用氯硝西泮(调整优势比3.86,95%CI 3.24 - 4.60)、地西泮(2.05,1.78 - 2.36)或阿普唑仑(1.76,1.52 - 2.03)与极高剂量使用的几率增加相关。中高剂量和极高剂量BZDR使用均与较低教育水平相关。总体而言,58%的极高剂量使用发生在从全科医生处获得首张处方的BZDR使用者中。
临床医生应意识到剂量增加的风险,尤其是在为精神科适应症开具地西泮、阿普唑仑或氯硝西泮处方时。如果需要使用BZDR,我们的研究结果表明倾向于使用奥沙西泮。